Kura Oncology Statistics

Total Valuation

Kura Oncology has a market cap or net worth of $557.54 million. The enterprise value is -$81.30 million.

Market Cap	557.54M
Enterprise Value	-81.30M

Important Dates

The next estimated earnings date is Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Kura Oncology has 86.57 million shares outstanding. The number of shares has increased by 12.88% in one year.

Current Share Class	86.57M
Shares Outstanding	86.57M
Shares Change (YoY)	+12.88%
Shares Change (QoQ)	+0.32%
Owned by Insiders (%)	0.80%
Owned by Institutions (%)	69.77%
Float	64.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.24
Forward PS	2.26
PB Ratio	1.43
P/TBV Ratio	1.53
P/FCF Ratio	5.04
P/OCF Ratio	5.01
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.07, with a Debt / Equity ratio of 0.05.

Current Ratio	8.07
Quick Ratio	7.93
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	0.18
Interest Coverage	-126.91

Financial Efficiency

Return on equity (ROE) is -41.84% and return on invested capital (ROIC) is -28.07%.

Return on Equity (ROE)	-41.84%
Return on Assets (ROA)	-19.60%
Return on Invested Capital (ROIC)	-28.07%
Return on Capital Employed (ROCE)	-31.11%
Revenue Per Employee	$354,120
Profits Per Employee	-$947,328
Employee Count	192
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

In the past 12 months, Kura Oncology has paid $2.24 million in taxes.

Income Tax	2.24M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.30% in the last 52 weeks. The beta is 0.40, so Kura Oncology's price volatility has been lower than the market average.

Beta (5Y)	0.40
52-Week Price Change	-70.30%
50-Day Moving Average	6.15
200-Day Moving Average	10.96
Relative Strength Index (RSI)	52.04
Average Volume (20 Days)	1,250,547

Short Selling Information

The latest short interest is 8.36 million, so 9.65% of the outstanding shares have been sold short.

Short Interest	8.36M
Short Previous Month	7.95M
Short % of Shares Out	9.65%
Short % of Float	13.03%
Short Ratio (days to cover)	6.94

Income Statement

In the last 12 months, Kura Oncology had revenue of $67.99 million and -$181.89 million in losses. Loss per share was -$2.09.

Revenue	67.99M
Gross Profit	-107.06M
Operating Income	-203.44M
Pretax Income	-181.75M
Net Income	-181.89M
EBITDA	-202.59M
EBIT	-203.44M
Loss Per Share	-$2.09

Full Income Statement

Balance Sheet

The company has $658.19 million in cash and $19.35 million in debt, giving a net cash position of $638.84 million or $7.38 per share.

Cash & Cash Equivalents	658.19M
Total Debt	19.35M
Net Cash	638.84M
Net Cash Per Share	$7.38
Equity (Book Value)	364.41M
Book Value Per Share	4.51
Working Capital	634.43M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $111.23 million and capital expenditures -$680,000, giving a free cash flow of $110.55 million.

Operating Cash Flow	111.23M
Capital Expenditures	-680,000
Free Cash Flow	110.55M
FCF Per Share	$1.28

Full Cash Flow Statement

Margins

Gross margin is -157.46%, with operating and profit margins of -299.22% and -267.52%.

Gross Margin	-157.46%
Operating Margin	-299.22%
Pretax Margin	-264.22%
Profit Margin	-267.52%
EBITDA Margin	-297.96%
EBIT Margin	-299.22%
FCF Margin	162.60%

Dividends & Yields

Kura Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.88%
Shareholder Yield	-12.88%
Earnings Yield	-32.62%
FCF Yield	19.83%

Analyst Forecast

The average price target for Kura Oncology is $24.50, which is 280.44% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$24.50
Price Target Difference	280.44%
Analyst Consensus	Strong Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	71.57%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kura Oncology has an Altman Z-Score of 0.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.35
Piotroski F-Score	3